InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a report released on Thursday. The firm set a "sell" rating on the stock.

Separately, Lake Street Capital initiated coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a "buy" rating and a $5.00 price target for the company.

InspireMD Stock Down 1.9 %

Shares of NYSE NSPR traded down $0.05 during trading hours on Thursday, hitting $2.59. The company had a trading volume of 34,728 shares, compared to its average volume of 33,908. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.80. The firm's 50 day moving average is $2.84 and its 200-day moving average is $2.75. The stock has a market capitalization of $76.90 million, a P/E ratio of -3.45 and a beta of 0.74.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Parkman Healthcare Partners LLC raised its stake in InspireMD by 721.2% in the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company's stock valued at $2,248,000 after acquiring an additional 750,635 shares during the period. Essex Investment Management Co. LLC acquired a new position in shares of InspireMD in the fourth quarter valued at $191,000. Northern Trust Corp increased its holdings in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after purchasing an additional 24,452 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its position in shares of InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after purchasing an additional 18,233 shares during the period. Finally, Legato Capital Management LLC acquired a new stake in shares of InspireMD during the 4th quarter worth about $47,000. 44.78% of the stock is currently owned by institutional investors.

Remove Ads

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.